Overview

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Status:
Not yet recruiting

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects with hTERT-positive GBM.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Rznomics, Inc.

Treatments:

Valganciclovir